Back
Zoetis, Inc. 10K Form
Sell
25
ZTS
Zoetis, Inc.
Last Price:
$127.26
Seasonality Move:
1.3%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-11-02 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-08-08 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2023-05-04 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2022-11-03 | 10Q | ZTS/Zoetis, Inc. Quarterly |
| 2022-08-04 | 10Q | ZTS/Zoetis, Inc. Quarterly |
Receive ZTS News And Ratings
See the #1 stock for the next 7 days that we like better than ZTS
ZTS Financial Statistics
Sales & Book Value
| Annual Sales: | $9.5B |
|---|---|
| Cash Flow: | $732M |
| Price / Cash Flow: | 24.74 |
| Annual Sales: | $7.84 |
| Price / Book: | 16.13 |
Profitability
| EPS (TTM): | 6.02180 |
|---|---|
| Net Income (TTM): | $2.7B |
| Gross Margin: | $6.7B |
| Return on Equity: | 57.78% |
| Return on Assets: | 18.2% |
Zoetis, Inc. Earnings Forecast
Key Zoetis, Inc. Financial Ratios
-
The Gross Profit Margin over the past 17 years for ZTS is 70.49%.
-
The Selling, General & Administrative Expenses for ZTS have been equal to 25.12% of Gross Profit Margin.
-
The Research & Development expenses have been 7.37% of Revenue.
-
The Interest Expense is 9.09% of Operating Income.
-
The Net Earning history of ZTS is 28.23% of Total Revenues.
-
Per Share Earnings over the last 17 years have been positive in 15 years.
Zoetis, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | ZTS |
| CUSIP: | 98978V |
| Website: | zoetis.com |
Debt
| Debt-to-Equity Ratio: | 2.79 |
|---|---|
| Current Ratio: | 3.03 |
| Quick Ratio: | 1.75 |
Price-to-Earnings
| Trailing P/E Ratio: | 21.13 |
|---|---|
| Forward P/E Ratio: | 16.85 |
ZTS Technical Analysis vs Fundamental Analysis
Sell
25
Zoetis, Inc. (ZTS)
is a Sell
Is Zoetis, Inc. a Buy or a Sell?
-
Zoetis, Inc. stock is rated a SellThe current Zoetis, Inc. [ZTS] share price is $127.28. The Score for ZTS is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.